DelistingOct 30, 2026, 04:07 PM
Neumora Therapeutics Faces Nasdaq Delisting Warning Over Low Stock Price
AI Summary
Neumora Therapeutics, Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. The company has 180 days, until April 26, 2027, to regain compliance. Failure to do so could lead to a transfer to The Nasdaq Capital Market or eventual delisting. Neumora is exploring options, including a reverse stock split, to address the deficiency.
Key Highlights
- Neumora Therapeutics received notice from Nasdaq for non-compliance with the $1.00 minimum bid price requirement.
- The company has until April 26, 2027, to regain compliance by having its stock close at or above $1.00 for ten consecutive business days.
- Failure to comply may result in a transfer to The Nasdaq Capital Market, subject to meeting other listing requirements.
- Neumora is considering options to resolve the noncompliance, including a potential reverse stock split.
Price Impact
More from NMRA